Jørgen Slots | Clinical Neuroscience |

Posted on by Neuroscientists

Prof. Dr. Jørgen Slots | Clinical Neuroscience | Best Researcher Award

Prof. Dr. Jørgen Slots, University of Southern California,  United States.

Dr. Jørgen Slots is an internationally recognized scholar in periodontology and oral microbiology, with a rich academic and professional background rooted in Denmark, the United States, and Sweden. After completing multiple advanced degrees—including a D.D.S., Ph.D., D.M.D., and M.B.A.—he held tenured and leadership roles at esteemed institutions such as the Royal Dental College, SUNYAB, and the University of Göteborg. His research focused on microbial causes of periodontal disease, bridging the gap between laboratory science and clinical treatment. Throughout his career, he has been a pioneer in integrating microbiology into dental education and has significantly influenced both teaching and clinical standards globally. His work continues to inform practices in oral health and inspire the next generation of researchers and clinicians.

Profile

Google Scholar

🎓 Early Academic Pursuits

Born in 1944 in Vejle, Denmark, Dr. Jørgen Slots embarked on a lifelong journey in dentistry and biomedical science that began at the prestigious Royal Dental College in Copenhagen. He earned his D.D.S. in 1969 and continued to delve deeper into academic excellence with an M.S. (Lic. Odont.) in 1974. His passion for periodontology led him to complete postgraduate education in this specialty by 1976, setting the stage for a research-intensive career. Not stopping there, he pursued advanced studies in microbiology at the Forsyth Dental Center in Boston, Massachusetts, where he earned a Certificate in Microbiology in 1977. By 1979, he had completed his doctoral thesis (Dr. Odont./Ph.D.), a reflection of his rigorous scientific training and commitment to academic inquiry.

🧪 Professional Endeavors in Dental Science

Dr. Slots’ career spans both private practice and academia, beginning with clinical work in Copenhagen from 1969 to 1976. However, his true calling was in academia and research, where he quickly rose through the ranks at the Royal Dental College, becoming a tenured associate professor in the Department of Periodontology and Bacteriology. His academic influence extended internationally as he moved to the United States, joining the State University of New York at Buffalo (SUNYAB) as a visiting associate professor in 1977. His multifaceted roles there included teaching, research, and graduate mentorship. In 1982, his expertise was recognized with a professorial and chair appointment at the University of Göteborg in Sweden, where he led the Department of Oral Microbiology until 1986.

🔬 Contributions and Research Focus

Dr. Slots’ core research has focused on periodontal microbiology, particularly the microbial etiology of periodontal diseases and the role of anaerobic bacteria in oral infections. His extensive background in both clinical periodontology and microbiology enabled him to bridge these disciplines, pioneering investigations into microbial pathogenesis, host responses, and antimicrobial therapy. His work at the intersection of dentistry and microbiology has contributed significantly to the understanding of how bacterial biofilms influence periodontal health and disease progression. Through his positions in leading institutions, he has mentored countless students and young researchers in translational oral biology.

🏅 Accolades and Recognition

Throughout his distinguished career, Dr. Slots has earned numerous accolades that acknowledge both his scholarly achievements and teaching excellence. His academic journey includes obtaining a D.M.D. from the University of Pennsylvania in 1986, further consolidating his clinical credentials. In 1989, he expanded his skillset by earning an M.B.A. from the Wharton School, indicating his interest in healthcare administration and leadership. Such accomplishments reflect a rare blend of scientific acumen, clinical expertise, and administrative insight that is seldom seen in one individual. His tenured appointments and leadership roles speak volumes about the respect he commands in his field.

🌍 Impact and Global Influence

Dr. Slots’ contributions have had global implications, influencing not only North American dental education but also shaping European periodontal research. His tenure at institutions in Denmark, Sweden, and the United States illustrates his international standing and thought leadership. By combining laboratory science with clinical application, he has contributed to international standards in oral hygiene practices, periodontal disease diagnostics, and treatment protocols. His collaborative work across continents has helped create a robust, evidence-based approach to periodontal care that is taught and practiced worldwide.

📚 Legacy in Dental Education and Microbiology

As a graduate faculty member and department chair, Dr. Slots played a vital role in curriculum development, graduate training, and interdisciplinary integration of oral microbiology into mainstream dental education. He has influenced a generation of oral biologists and periodontists who continue to build upon his foundational work. His teaching style, grounded in research and clinical relevance, made him a beloved educator and mentor. The ripple effects of his academic stewardship can still be seen in the progressive research and pedagogical models employed at the University of Southern California and other leading dental institutions.

🔭 Future Vision and Continuing Relevance

Though his primary academic career has matured, the legacy of Dr. Slots remains very much alive in ongoing research studies, collaborative clinical trials, and academic dialogues. His integration of clinical practice with microbiological research stands as a model for future dental scientists aiming to address emerging challenges in oral-systemic health. With a unique blend of intellectual rigor and compassionate mentorship, Dr. Slots has laid a foundation that will support future breakthroughs in both academic and applied dental sciences. His life’s work continues to inspire innovation and scientific inquiry in oral health worldwide.

Publication

Polymerase chain reaction detection of 8 putative periodontal pathogens in subgingival plaque of gingivitis and advanced periodontitis lesions
A Ashimoto, C Chen, I Bakker, J Slots – 1996

Subgingival microflora and periodontal disease
J Slots – 1979

Periodontitis: facts, fallacies and the future
J Slots – 2017

Black-pigmented Bacteroides species, Capnocytophaga species, and Actinobacillus actinomycetemcomitans in human periodontal disease: virulence factors in colonization, survival
J Slots, RJ Genco – 1984

Bacteroides gingivalis, Bacteroides intermedius and Actinobacillus actinomycetemcomitans in human periodontal diseases
J Slots, MA Listgarten – 1988

Selective medium for isolation of Actinobacillus actinomycetemcomitans
J Slots – 1982

Actinobacillus actinomycetemcomitans in Human Periodontal Disease: a Cross-Sectional Microbiological Investigation
J Slots, HS Reynolds, RJ Genco – 1980

Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases
ILC Chapple, R Genco, Working Group 2 of the Joint EFP/AAP Workshop – 2013

The occurrence of Actinobacillus actinomycetemcomitans, Bacteroides gingivalis and Bacteroides intermedius in destructive periodontal disease in adults
J Slots, L Bragd, M Wikström, G Dahlén – 1986

Actinobacillus actinomycetemcomitans and Porphyromonas gingivalis in human periodontal disease: occurrence and treatment
J Slots, M Ting – 1999

Antibiotics in periodontal therapy: advantages and disadvantages
J Slots, TE Rams – 1990

The predominant cultivable microflora of advanced periodontitis
J Slots – 1977

Actinobacillus actinomycetemcomitans in Human Periodontal Disease: Prevalence in Patient Groups and Distribution of Biotypes and Serotypes Within Families
JJ Zambon, LA Christersson, J Slots – 1983

Systemic antibiotic therapy in periodontics
AJV Winkelhoff, TE Rams, J Slots – 1996

Microbial differences in 2 clinically distinct types of failures of osseointegrated implants
ES Rosenberg, JP Torosian, J Slots – 1991

The predominant cultivable organisms in juvenile periodontitis
J Slots – 1976

Suppression of the periodontopathic microflora in localized juvenile periodontitis by systemic tetracycline
J Slots, BG Rosling – 1983

Periodontal therapy in humans. I. Microbiological and clinical effects of a single course of periodontal scaling and root planing, and of adjunctive tetracycline therapy
J Slots, P Mashimo, MJ Levine, RJ Genco – 1979

Serology of oral Actinobacillus actinomycetemcomitans and serotype distribution in human periodontal disease
JJ Zambon, J Slots, RJ Genco – 1983

🏁 Conclusion

Dr. Jørgen Slots’ career stands as a remarkable example of interdisciplinary excellence in dental science. Through his research in periodontal microbiology, leadership in academic institutions, and dedication to global dental education, he has left a lasting legacy. His contributions have not only advanced scientific knowledge but also improved clinical approaches to oral healthcare worldwide. Dr. Slots remains a towering figure whose impact resonates in the fields of periodontology, microbiology, and beyond.

Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Posted on by Neuroscientists

Dr. Liliana Elena Weimer | Clinical Neuroscience | Best Researcher Award

Dr.  Liliana Elena Weimer, Center For Global Health Istituto Superiore di Sanita’ Rome, Italy.

Dr. Liliana Elena Weimer is a highly accomplished physician and clinical researcher , where she has risen to the prestigious Level II “First Researcher” position. Her professional focus lies in clinical trials for infectious diseases, particularly HIV and Hepatitis C. She has played a critical role in major national and international research efforts, including collaborations with the U.S. Clinical Trials Group and leadership of the large-scale PITER cohort involving 25,000 HCV patients. She is known not only for her scientific contributions but also for her humanitarian efforts during the COVID-19 emergency. Among her recognitions is the 1st Prize at the 2019 International Congress on Hepatitis C in Seville. Throughout her career, she has exemplified scientific integrity, dedication, and service to public health.

Profile

Google Scholar

🎓 Early Academic Pursuits

Born on December 19, 1965, in Buenos Aires to Italian parents, Dr. Liliana Elena Weimer embraced her dual heritage and committed herself to a life in medicine and research. With Italian citizenship and deep academic determination, she laid the groundwork for her career by studying medicine, ultimately finding her professional home in Italy. Her academic path, though not fully detailed, clearly led her toward a focus on clinical medicine and infectious diseases, with her earliest professional roles marking the beginning of a lifelong engagement in public health and biomedical research. Her intellectual dedication and international roots later became an asset in global research collaborations.

🩺 Professional Endeavors

Dr. Weimer’s distinguished career spans over three decades at the Italian National Institute of Health (ISS), beginning in 1985. Starting as a dedicated clinical physician, she ascended to Level III researcher status by 1990 and continued to grow into higher ranks, culminating in her success in the national Art. 15 competition for the Level II “First Researcher” role in 2022, officially backdated to 2021. Throughout her tenure at ISS, she became a central figure within the Global Health Center in Rome. Known for her tireless commitment, she often described her career not simply as a job but as a “mission,” emphasizing both her personal and professional passion for making a difference in human health.

🧪 Contributions and Research Focus

Specializing in clinical trials, Dr. Weimer has coordinated and participated in numerous groundbreaking studies in HIV and Hepatitis C (HCV). Since the early 1990s, she has collaborated closely with renowned figures such as Prof. Giovanni Rossi, Prof. Stefano Vella, and Prof. Gianni Rezza, contributing to some of the most pivotal HIV antiretroviral therapy trials in history. Her research efforts extended to co-leading and organizing both national and international multicenter clinical trials. Notably, she has been at the forefront of the PITER study, a major nationwide cohort that follows 25,000 patients undergoing HCV treatment—one of the most comprehensive initiatives in Italy in the fight against hepatitis.

🌍 Global Collaborations and Humanitarian Engagement

Her impact extends beyond Italy, thanks to her active involvement with the U.S.-based American Clinical Trials Group on HIV studies. These collaborations have enhanced international understanding and treatment of HIV/AIDS. In addition to her clinical and research commitments, Dr. Weimer also devoted herself to frontline service during the COVID-19 pandemic. Volunteering both with the Civil Protection unit and at Bambino Gesù Children’s Hospital, she demonstrated profound humanitarian values. Her presence during a critical time underscored her belief in serving communities not just from behind a lab desk but also on the ground, directly supporting patients and health systems under strain.

🏅 Accolades and Recognition

Dr. Weimer’s work has been acknowledged at both national and international levels. One of the most prominent recognitions she received was the 1st Prize at the International Congress on Hepatitis C held in Seville in November 2019, a testament to her excellence and influence in the field of infectious disease research. Her achievements are not only measured in accolades but also in the tangible difference her work has made in advancing therapy options and clinical management of chronic viral diseases. Her rise within the ISS and the trust placed in her leadership of major research projects further affirm her standing within the scientific community.

💡 Impact and Influence

Over the course of her extensive career, Dr. Weimer has significantly shaped clinical research strategies in Italy, especially regarding chronic viral infections. Her coordination of thousands of patient cases within structured clinical trials has informed policy decisions and improved treatment protocols nationwide. Her presence at the ISS has also influenced future generations of researchers and clinicians, many of whom benefited from her mentorship, leadership, and example of scientific integrity. Through her rigorous methods and patient-focused approach, she has played a key role in Italy’s standing as a leader in global health research, especially in relation to HIV and HCV.

🔬 Legacy and Future Contributions

Looking forward, Dr. Weimer’s contributions will continue to echo through the fields of virology and clinical medicine. Her involvement in the PITER cohort and other studies has laid down essential groundwork for long-term epidemiological surveillance and patient care strategies. With her appointment as First Researcher, she enters a new chapter of leadership, likely to drive more innovative, patient-centered research initiatives in global health. Her legacy lies not only in her publications or awards but also in the thousands of lives improved by the treatments she helped to test, refine, and implement. The combination of scientific rigor and heartfelt service defines her enduring contribution to modern medicine.

Publication

  • Outcome of sustained virological responders with histologically advanced chronic hepatitis C – TR Morgan, MG Ghany, HY Kim, KK Snow, ML Shiffman, JL De Santo, … – 2010

 

  • Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5‐year follow‐up of 150 patients – SL George, BR Bacon, EM Brunt, KL Mihindukulasuriya, J Hoffmann, … – 2009

 

  • Safety and efficacy of simeprevir/sofosbuvir in hepatitis C–infected patients with compensated and decompensated cirrhosis – V Saxena, L Nyberg, M Pauly, A Dasgupta, A Nyberg, B Piasecki, … – 2015

 

  • Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy – D Persaud, SC Ray, J Kajdas, A Ahonkhai, GK Siberry, K Ferguson, … – 2007

 

  • Evaluation of proton pump inhibitor use on treatment outcomes with ledipasvir and sofosbuvir in a real‐world cohort study – EB Tapper, BR Bacon, MP Curry, DT Dieterich, SL Flamm, LE Guest, … – 2016

 

  • Microbial translocation is associated with residual viral replication in HAART-treated HIV+ subjects with< 50 copies/ml HIV-1 RNA – S Baroncelli, CM Galluzzo, MF Pirillo, MG Mancini, LE Weimer, … – 2009

 

  • Predictors of failure with high-flow nasal oxygen therapy in COVID-19 patients with acute respiratory failure: a multicenter observational study – R Mellado-Artigas, LE Mujica, ML Ruiz, BL Ferreyro, F Angriman, E Arruti, … – 2021

 

  • A randomized, double-blind trial on the use of a triple combination including nevirapine, a nonnucleoside reverse transcriptase HIV inhibitor, in antiretroviral-naive patients – M Floridia, R Bucciardini, D Ricciardulli, V Fragola, MF Pirillo, LE Weimer, … – 1999

 

  • Modeling cost‐effectiveness and health gains of a “universal” versus “prioritized” hepatitis C virus treatment policy in a real‐life cohort – LA Kondili, F Romano, FR Rolli, M Ruggeri, S Rosato, MR Brunetto, … – 2017

 

  • Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER network – LA Kondili, GB Gaeta, D Ieluzzi, AL Zignego, M Monti, A Gori, A Soria, … – 2017

 

🏁 Conclusion

Dr. Weimer stands as a distinguished figure in the field of global health research, with deep expertise in clinical trials and infectious diseases. Her legacy is marked by landmark contributions to HIV and HCV treatment protocols, influential collaborations, and compassionate public service. Her ongoing work continues to shape public health policy and medical research in Italy and beyond. As she advances in her leadership role at the ISS, her experience, insight, and dedication will remain vital to future innovations in clinical research and global health.